- GSK (GSK) has called it quits on its GSK2586184 treatment for lupus - which it's developing with Belgian biotech Galapagos (GLPGF) - after a Phase 2 study failed to demonstrate a positive effect. A Phase1/2 trial for ulcerative colitis was put on hold as well, although dosing in a Phase 2 trial for the skin condition psoriasis has just been completed.
- Galapagos' relationship with Glaxo goes back seven years and included $300M in potential milestone payments. Galapagos was in line for a $34M payment for the start of the Phase 2 study.
- Glaxo's decision over lupus shows its willingness to end development that's not working - last year, the company pulled the plug on ChemoCentryx's Vercirnon, abruptly ending a $1.5B collaboration after a Phase 3 trial failed. (PR)
Glaxo pulls the plug on lupus drug development
From other sites
at CNBC.com (May 28, 2015)
Video at CNBC.com (May 11, 2015)
Video at CNBC.com (May 6, 2015)
Video at CNBC.com (Jan 23, 2015)
at CNBC.com (Jan 6, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs